Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection Topline results expected in Q1 2020 DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics...
New Patient Access Survey Shows Consumers Are Increasingly Self-Empowered in Their Care Decisions and Place a Growing Premium on Convenience Third Annual Survey from Kyruus Underscores the Need for Health Systems to Meet Patient Demand for Streamlined Access and...
Neurana Pharmaceuticals Appoints Randall Kaye, M.D., Chief Medical Officer SAN DIEGO, Calif., November 7, 2019 – Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that it has appointed...
ARVINAS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the...
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions 200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications Top-line...
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting Study met primary and secondary endpoints – statistically significant effects on neuroimaging...
Recent Comments